In The News Posted March 7, 2019 Share Posted March 7, 2019 CORK, Ireland, March 7, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson confirmed that the novel, investigational, long-acting two-drug injectable regimen of rilpivirine and cabotegravir met its primary endpoints in two major Phase 3 studies - the... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.